Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Invitrogen: New Herceptin Candidate Dx Gives More Labs A Chance To Test

This article was originally published in The Gray Sheet

Executive Summary

Invitrogen's SPOT-Light HER2 test, PMA-approved by FDA July 8, will not be the first kit in the U.S. to help physicians decide if a breast cancer patient will benefit from Genentech's Herceptin therapy, but it will allow a host of new laboratories to perform the analysis, according to the firm
Advertisement

Related Content

Invitrogen Herceptin candidate Dx launches
Invitrogen Herceptin candidate Dx launches
Advertisement
UsernamePublicRestriction

Register

MT026328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel